Bone
metastasis is a frequent occurrence in
prostate cancer (PCa) that is associated with severe complications such as
fracture, bone pain and
hypercalcemia. The cross-talk between metastatic
cancer cells and bone is critical to the development and progression of bone
metastases. In our previous data, we have described how the involvement of the Wnt-induced secreted
protein-1/
vascular cell adhesion molecule-1 (WISP-1/VCAM-1) system in this
tumor-bone interaction contributes to human PCa cell motility. In this study, we found that WISP-1 regulates bone mineralization by inducing bone morphogenetic protein-2 (BMP2), BMP4 and
osteopontin (OPN) expression in osteoblasts. We also found that WISP-1 inhibited RANKL-dependent osteoclastogenesis. Moreover, osteoblast-derived WISP-1 enhanced
VCAM-1 expression in PCa cells and subsequently promoted the adherence of
cancer cells to osteoblasts. Furthermore,
endothelin-1 (ET-1) expression in PCa cells was regulated by osteoblast-derived WISP-1, which promoted
integrin α4β1 expression in osteoblasts via the MAPK pathway. Pretreatment of PCa cells with
VCAM-1 antibody or osteoblasts with
integrin α4β1 antibody attenuated the adherence of PCa cells to osteoblasts, suggesting that
integrin α4β1 serves as a
ligand that captures VCAM-1+ metastatic
tumor cells adhering to osteoblasts. Our findings reveal that osteoblast-derived WISP-1 plays a key role in regulating the adhesion of PCa cells to osteoblasts via the VCAM-1/
integrin α4β1 system. Osteoblast-derived WISP-1 is a promising target for the prevention and inhibition of PCa-bone interaction.